Skip to main content
Erschienen in: Rheumatology International 9/2011

01.09.2011 | Original Article

Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus

verfasst von: Hyoun-Ah Kim, Jun-Mo Sung, Ja-Young Jeon, Jeong-Moon Yoon, Chang-Hee Suh

Erschienen in: Rheumatology International | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Vitamin D is a pleiotrophic hormone with immunoregulatory properties. Low levels of vitamin D have been discovered in various autoimmune diseases. Here, we investigated serum vitamin D levels in Koreans with systemic lupus erythematosus (SLE) and examined whether levels correlate with disease activity of SLE. Blood samples were prospectively collected from patients with SLE (n = 104) and normal controls (NC, n = 49) during the spring from March to May 2008. The level of serum 25-hydroxyvitamin D (25(OH)D3) was measured by radioimmunoassay. The serum 25(OH)D3 levels of patients with SLE (42.49 ± 15.08 ng/ml) were significantly lower than NC (52.72 ± 15.19 ng/ml, P < 0.001). Additionally, 17 patients with SLE (16.3%) had vitamin D insufficiency, while two NC had vitamin D insufficiency (4.1%). The risk of vitamin D insufficiency was 4.6-fold increased in SLE (P = 0.032). The serum 25(OH)D3 levels, adjusted with BMI, were positively correlated only with hemoglobin (β = 0.256, P = 0.018) and serum complement 3 (β = 0.365, P = 0.002). Serum vitamin D levels were lower, and vitamin D insufficiency was more common in Korean patients with SLE, however, our study demonstrated that vitamin D levels might not be a good marker of disease activity.
Literatur
2.
Zurück zum Zitat van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101PubMedCrossRef van Etten E, Mathieu C (2005) Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101PubMedCrossRef
3.
Zurück zum Zitat Bhalla AK, Amento EP, Serog B et al (1984) 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133:1748–1754PubMed Bhalla AK, Amento EP, Serog B et al (1984) 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J Immunol 133:1748–1754PubMed
4.
Zurück zum Zitat Lemire JM (1992) Immunomodulatory role of 1, 25-dihydroxyvitamin D3. J Cell Biochem 49:26–31PubMedCrossRef Lemire JM (1992) Immunomodulatory role of 1, 25-dihydroxyvitamin D3. J Cell Biochem 49:26–31PubMedCrossRef
5.
Zurück zum Zitat Mattner F, Smiroldo S, Galbiati F et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol 30:498–508PubMedCrossRef Mattner F, Smiroldo S, Galbiati F et al (2000) Inhibition of Th1 development and treatment of chronic-relapsing experimental allergic encephalomyelitis by a non-hypercalcemic analogue of 1, 25-dihydroxyvitamin D(3). Eur J Immunol 30:498–508PubMedCrossRef
6.
Zurück zum Zitat Linker-Israeli M, Elstner E, Klinenberg JR et al (2001) Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 99:82–93PubMedCrossRef Linker-Israeli M, Elstner E, Klinenberg JR et al (2001) Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol 99:82–93PubMedCrossRef
7.
Zurück zum Zitat Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362–371PubMed Holick MF (2004) Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362–371PubMed
8.
Zurück zum Zitat Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 229:1136–1142 Cantorna MT, Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 229:1136–1142
9.
Zurück zum Zitat Bultink IE, Lems WF, Kostense PJ et al (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050PubMedCrossRef Bultink IE, Lems WF, Kostense PJ et al (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050PubMedCrossRef
10.
Zurück zum Zitat Muller K, Kriegbaum NJ, Baslund B et al (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14:397–400PubMedCrossRef Muller K, Kriegbaum NJ, Baslund B et al (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14:397–400PubMedCrossRef
11.
Zurück zum Zitat Huisman AM, White KP, Algra A et al (2001) Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 28:2535–2539PubMed Huisman AM, White KP, Algra A et al (2001) Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 28:2535–2539PubMed
12.
Zurück zum Zitat Kamen DL, Cooper GS, Bouali H et al (2006) Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 5:114–117PubMedCrossRef Kamen DL, Cooper GS, Bouali H et al (2006) Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 5:114–117PubMedCrossRef
14.
Zurück zum Zitat Chen S, Sims GP, Chen XX et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMed Chen S, Sims GP, Chen XX et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179:1634–1647PubMed
15.
Zurück zum Zitat Orbach H, Zandman-Goddard G, Amital H et al (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109:385–400PubMedCrossRef Orbach H, Zandman-Goddard G, Amital H et al (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 1109:385–400PubMedCrossRef
16.
Zurück zum Zitat Ruiz-Irastorza G, Egurbide MV, Olivares N et al (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2047:920–923CrossRef Ruiz-Irastorza G, Egurbide MV, Olivares N et al (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 2047:920–923CrossRef
17.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedCrossRef
18.
Zurück zum Zitat Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI.A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35:630–640PubMedCrossRef
19.
Zurück zum Zitat Gladman DD, Goldsmith CH, Urowitz MB et al (2000) The systemic lupus international collaborating clinics/American college of rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373–376PubMed Gladman DD, Goldsmith CH, Urowitz MB et al (2000) The systemic lupus international collaborating clinics/American college of rheumatology (SLICC/ACR) damage index for systemic lupus erythematosus international comparison. J Rheumatol 27:373–376PubMed
20.
Zurück zum Zitat Kim HA, Jeon JY, Choi GS et al (2008) The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol 128:277–283PubMedCrossRef Kim HA, Jeon JY, Choi GS et al (2008) The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol 128:277–283PubMedCrossRef
21.
Zurück zum Zitat O’Regan S, Chesney RW, Hamstra A et al (1979) Reduced serum 1, 25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 68:109–111PubMedCrossRef O’Regan S, Chesney RW, Hamstra A et al (1979) Reduced serum 1, 25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 68:109–111PubMedCrossRef
22.
Zurück zum Zitat Borba VZ, Vieira JG, Kasamatsu T et al (2009) Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 20:427–433PubMedCrossRef Borba VZ, Vieira JG, Kasamatsu T et al (2009) Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 20:427–433PubMedCrossRef
23.
Zurück zum Zitat Thudi A, Yin S, Wandstrat AE et al (2008) Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 335:99–104PubMedCrossRef Thudi A, Yin S, Wandstrat AE et al (2008) Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci 335:99–104PubMedCrossRef
24.
Zurück zum Zitat Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67:373–378PubMedCrossRef Webb AR, Kline L, Holick MF (1988) Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67:373–378PubMedCrossRef
25.
Zurück zum Zitat Klein RG, Arnaud SB, Gallagher JC et al (1977) Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 60:253–259PubMedCrossRef Klein RG, Arnaud SB, Gallagher JC et al (1977) Intestinal calcium absorption in exogenous hypercortisonism. Role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 60:253–259PubMedCrossRef
26.
Zurück zum Zitat Hahn TJ, Halstead LR, Haddad JG Jr (1977) Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 90:399–404PubMed Hahn TJ, Halstead LR, Haddad JG Jr (1977) Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy. J Lab Clin Med 90:399–404PubMed
27.
Zurück zum Zitat O’Leary TJ, Jones G, Yip A (1986) The effects of chloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315:727–730PubMedCrossRef O’Leary TJ, Jones G, Yip A (1986) The effects of chloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. N Engl J Med 315:727–730PubMedCrossRef
28.
Zurück zum Zitat Zold E, Szodoray P, Gaal J et al (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123PubMedCrossRef Zold E, Szodoray P, Gaal J et al (2008) Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther 10:R123PubMedCrossRef
29.
Zurück zum Zitat Costenbader KH, Feskanich D, Holmes M et al (2008) Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 67:530–535PubMedCrossRef Costenbader KH, Feskanich D, Holmes M et al (2008) Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. Ann Rheum Dis 67:530–535PubMedCrossRef
Metadaten
Titel
Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus
verfasst von
Hyoun-Ah Kim
Jun-Mo Sung
Ja-Young Jeon
Jeong-Moon Yoon
Chang-Hee Suh
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 9/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1442-1

Weitere Artikel der Ausgabe 9/2011

Rheumatology International 9/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.